Biotech

All Articles

Vaxcyte rises on 'stunning' 31-valent PCV gain against Pfizer

.Vaxcyte revealed what experts named "magnificent" phase 1/2 data for its 31-valent pneumococcal vac...

Recursion's mind disease trial reveals insufficient evidence of effectiveness

.Recursion has actually discovered with an early exam of its tech-enabled technique to drug discover...

Acepodia, Pfizer click together for chemistry-based tissue treatment

.Call it an instance of good chemistry: Acepodia, a biotech based on Nobel Champion scientific resea...

Praxis epilepsy drug lessens seizures in phase 2 litigation

.Practice Accuracy Medicines has scored one more midphase win in epilepsy this year, along with its ...

Three directors resign as Dyne posts mixed data for DMD prospect

.After leaving a medical grip many years back, Dyne Therapeutics has actually disclosed brand-new ph...

Arrowhead fires off phase 3 data in uncommon metabolic ailment in front of market encounter Ionis

.Arrowhead Pharmaceuticals has actually revealed its give in advance of a possible face-off along wi...

Pfizer, Valneva reveal lyme health condition chance successful for second booster

.Pfizer and also Valneva may possess concerning pair of more years to stand by prior to they produce...

Fierce Biotech Editor-in-Chief Ayla Ellison Talks Patronize Michelle Benz on the Future of Biotech.

.Allow's dive into a discussion along with Ayla Ellison, Fierce Biotech Managing Editor and Michelle...

New records show how Bayer's asundexian fell short to stop strokes

.Bayer put on hold the phase 3 test for its own factor XIa inhibitor asundexian behind time in 2014 ...

Sanofi's tolebrutinib fails 2 of 3 late-stage MS trials

.Sanofi is still set on taking its numerous sclerosis (MS) med tolebrutinib to the FDA, managers hav...